Company: HUM
Filing Date: 2025-03-28
Form Type: 424B5
Source: 0001628280-25-015313
Chunk: 13

Company: HUMANA INC
Filing Date: 2025-03-28
Form: 424B5
Chunk 13
---
 issuance costs and exclude accrued interest on the additional 2031 notes from October 15, 2024, to but excluding the settlement date, totaling $6,196,180.56.

(4) Includes the 2035 Notes and the 2055 Notes, net of approximately $6.1 million of original issue discount and $13.1 million related to debt issuance costs.

(5) As of December 31, 2024, we had no borrowings outstanding under our Revolving Credit Facility or our 364-day Credit Facility and approximately $18 million of letters of credit outstanding under the Revolving Credit Facility. Accordingly, as of December 31, 2024, we had approximately $2.624 billion of remaining borrowing capacity under the Revolving Credit Facility and $2.1 billion of remaining borrowing capacity under the 364-day Credit Facility (which excludes an uncommitted $500 million of incremental loan facilities).

<div align='center'>S-6</div>

Table of Content s

### USE OF PROCEEDS
We estimate that our net proceeds from the issuance and sale of the additional 2031 notes will be approximately $247 million, excluding accrued interest on the additional 2031 notes and after deducting underwriters’ discounts and our estimated offering expenses. We intend to use the net proceeds from this offering for general corporate purposes, which may include the repayment of existing indebtedness.

If we do not use the net proceeds immediately, we will temporarily invest them in short-term, interest-bearing obligations.

<div align='center'>S-7</div>

Table of Content s

### DESCRIPTION OF THE NOTES
The following description of the additional 2031 notes offered hereby supplements the more general description of the debt securities that appears in the accompanying prospectus. You should read this section together with the section entitled “Description of the Debt Securities” in the accompanying prospectus. If there are any inconsistencies between the information in this section and the information in the accompanying prospectus, the information in this section controls and will apply to the additional 2031 notes.

The additional 2031 notes will be issued under the base indenture dated as of August 5, 2003 (the “base indenture”), between Humana and The Bank of New York Mellon Trust Company, N.A. (formerly known as The Bank of New York Trust Company, N.A.) (as successor to The Bank of New York), as trustee (the “trustee”), as supplemented by the twenty-eighth supplemental indenture, dated